Dr MacSweeney talks prevention with the Daily Express

Re:Cognition Health’s CEO & Medical Director has been featured in the Daily Express talking about a new, ground-breaking clinical trial for Alzheimer’s which aims to stop the disease from developing.

As one of the UK’s leading neuroradiologists, Dr MacSweeney shared her optimism for the new study, which will enable individuals to take control of their own health and influence their future in the fight against Alzheimer’s disease.

Prevention of Alzheimer's disease

The Generation Study is screening thousands of healthy participants aged between 60-75 years at Re:Cognition Health Clinics in the UK, all of whom show no sign of cognitive decline.

Volunteers will have a swab taken from their cheek to identify individuals who carry a specific gene which makes them at higher risk of developing Alzheimer’s disease.

Those who carry the APOE4 gene will be considered to participate in the Generation Study, which will last between 5-8 years.

Dr Emer MacSweeney

For the first time the opportunity exists for those at risk to gain early access to these new medicines to prevent the disease occurring in the first place or slow it downDr Emer MacSweeney (above)

The APOE4 gene can increase the risk of developing Alzheimer’s disease. The treatment being tested in the Generation Study may be able to prevent amyloid-β protein plaques from forming in the brain, which is thought to be responsible for the development of Alzheimer’s disease.

These plaques can start forming by as much as 20 years before symptoms of Alzheimer’s disease begin to present. Find out more by selecting one of the buttons below

 

 

 

Back To All News